3,7-dihydroxydibenzo[b,d]thiophene 5,5-dioxide | 67588-04-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 苯并噻吩类
• 英文名称: 3,7-dihydroxydibenzo[b,d]thiophene 5,5-dioxide
• 英文别名: 3,7-dihydroxybenzothiophene-5,5-dioxide；5,5-Dioxodibenzothiophene-3,7-diol
• CAS: 67588-04-9
• 化学式: C₁₂H₈O₄S
• 分子量: 248.259
• InChiKey: XBFYNXRMGOVHFX-UHFFFAOYSA-N

物化性质

• 熔点：
  325-327 °C
• 沸点：
  597.5±43.0 °C(Predicted)
• 密度：
  1.635±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  17
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,7-dihydroxydibenzo[b,d]thiophene 5,5-dioxide 、 (R)-(-)-3-奎宁醇 在 偶氮二甲酸二叔丁酯 、 polymer-bound triphenylphosphine 作用下， 以 四氢呋喃 为溶剂， 反应 16.0h， 以27%的产率得到3,7-bis[(3S)-1-azabicyclo[2.2.2]octan-3-yloxy]-dibenzothiophene
  参考文献：
  名称：

  Amino-substituted tricyclic derivatives and methods of use

  摘要：

  式（I）的化合物 其中A和B是胺基取代的侧链，Y 1 和Y 2 形成各种三环核，X a 和X b 为C、CH或N，如本文所定义，R x 是可选的取代基。考虑到式（I）的化合物和组合物，以及用于治疗由α7nAChR配体预防或改善的疾病或疾病的方法，这些方法涵盖了式（I）的化合物和其他三环衍生物。本文还描述了使用氨基取代的三环衍生物的方法。

  公开号：

  US20050234031A1
• 作为产物：
  描述：

  3,7-二溴-5,5-二氧-二苯并噻吩 在 tris-(dibenzylideneacetone)dipalladium(0) 、 potassium hydroxide 、 2-二-叔丁膦基-2',4',6'-三异丙基联苯 作用下， 以 1,4-二氧六环 、 水 为溶剂， 反应 16.0h， 以76%的产率得到3,7-dihydroxydibenzo[b,d]thiophene 5,5-dioxide
  参考文献：
  名称：

  基于SNAr的硫杂芳烃的“芳香变态”无过渡金属合成的咔唑和吲哚

  摘要：

  通过母体二苯并噻​​吩的氧化容易制备的二苯并噻吩二氧化物在一次操作中在分子内然后在分子内经历苯胺的亲核芳香取代，然后生成分子内相应的咔唑。二苯并噻吩向咔唑的“芳香变形”不需要任何重金属。该策略也适用于吲哚的合成。由于缺电子的硫杂芳烃二氧化物表现出有趣的反应性，而相应的富电子氮杂芳烃则未观察到，因此，二氧化硫杂ar特定反应与基于S N Ar的芳族变态反应的结合，使得无过渡金属的结构成为可能。难以制备咔唑。

  DOI：

  10.1002/anie.201503671

文献信息

• Novel substituted tricyclic compounds
  申请人：——

  公开号：US20030040538A1

  公开（公告）日：2003-02-27

  Compounds of the general formula (I) are useful in the treatment and prevention of &bgr;3-related diseases including diabetes, obesity and hyperlipidemia wherein R 1 is hydrogen, halogen, or hydroxyl; R 2 is C 1-4 alkyl or benzyl; R 3 is OR, halogen, trifluoromethyl, C 1-8 alkyl, lower acyl, NR 4 R 4′ , nitro, or cyano; R is hydrogen, C 1-8 alkyl, benzyl group, or optionally substituted lower acyl; R 4 and R 4′ are each independently hydrogen, C 1-4 alkyl, lower acyl, benzyl, or SO 2 R 5 ; R 5 is C 1-4 alkyl or benzyl; W is oxygen, a secondary nitrogen atom (NH), or sulfur; and * represents an asymmetric carbon atom. 1

  通式（I）的化合物在治疗和预防与β3相关的疾病，包括糖尿病、肥胖症和高脂血症方面具有用处，其中R1是氢、卤素或羟基；R2是C1-4烷基或苄基；R3是OR、卤素、三氟甲基、C1-8烷基、较低酰基、NR4R4'、硝基或氰基；R是氢、C1-8烷基、苄基或可选取代的较低酰基；R4和R4'各自独立地为氢、C1-4烷基、较低酰基、苄基或SO2R5；R5是C1-4烷基或苄基；W是氧、次级氮原子（NH）或硫；*代表不对称碳原子。
• NOVEL SUBSTITUTED TRICYCLIC COMPOUNDS
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP1238973A1

  公开（公告）日：2002-09-11

  Compounds of the general formula (I) are useful in the treatment and prevention of β3-related diseases including diabetes, obesity and hyperlipidemia wherein R1 is hydrogen, halogen, or hydroxyl; R2 is lower alkyl or benzyl; R3 is OR, halogen, trifluoromethyl, lower alkyl, lower acyl, NR4R4', nitro, or cyano; R is hydrogen, lower alkyl, benzyl group, or optionally substituted lower acyl; R4 and R4' are each independently hydrogen, lower alkyl, lower acyl, benzyl, or SO2R5; R5 is lower alkyl or benzyl; W is oxygen, a secondary nitrogen atom (NH), or sulfur; and * represents an asymmetric carbon atom.

  通式（I）化合物可用于治疗和预防与β3 有关的疾病，包括糖尿病、肥胖症和高脂血症 其中 R1 是氢、卤素或羟基；R2 是低级烷基或苄基；R3 是 OR、卤素、三氟甲基、低级烷基、低级酰基、NR4R4'、硝基或氰基；R 是氢、低级烷基、苄基或任选取代的低级酰基；R4 和 R4'各自独立地是氢、低级烷基、低级酰基、苄基或 SO2R5；R5 是低级烷基或苄基；W 是氧、仲氮原子 (NH) 或硫；以及 * 代表不对称碳原子。
• NOVEL REMEDIES WITH THE USE OF BETA3 AGONIST
  申请人：Asahi Kasei Kabushiki Kaisha

  公开号：EP1258253A1

  公开（公告）日：2002-11-20

  Provided is a therapeutic agent comprising at least a compound having a β3 agonist activity and one member selected from the group consisting of an anticholinergic agent, a monoamine reuptake inhibitor, a lipase inhibitor, a selective serotonin reuptake inhibitor, insulin, an insulin secretagogue, biguanide, an α-glucosidase inhibitor, an insulin sensitizer, a HMG-CoA reductase inhibitor, an anion exchange resin, a fibric acid derivative and a nicotinic acid derivative. The β3-agonist has an activity of inhibiting urinary incontinence. Further, when used together with a remedy for urinary incontinence such as propiverine, oxybutynin hydrochloride or tolterodine, it exerts an enhanced anti-urinary incontinence effect. When used together with an antiobestic agent such as sibutramine or orlistat, it exerts an enhanced antiobestic effect. When used together with an antidiabetic agent such as insulin, glibenclamide, acarbose or rosiglitazone, it exerts an enhanced antidiabetic effect. When used together with an antilipemic agent such as bezafibrate or pravastatin, it exerts an enhanced antilipemic effect.

  选择性 5-羟色胺再摄取抑制剂、胰岛素、胰岛素促泌剂、双胍类、α-葡萄糖苷酶抑制剂、胰岛素增敏剂、HMG-CoA 还原酶抑制剂、阴离子交换树脂、纤维酸衍生物和烟酸衍生物。β3-激动剂具有抑制尿失禁的活性。此外，当与治疗尿失禁的药物，如丙哌瑞林、盐酸奥昔布宁或托特罗定一起使用时，其抗尿失禁的效果会增强。与西布曲明或奥利司他等抗呕吐剂一起使用时，可增强抗呕吐效果。与胰岛素、格列本脲、阿卡波糖或罗格列酮等抗糖尿病药同时使用时，可增强抗糖尿病效果。与贝扎贝特或普伐他汀等抗血脂药同时使用时，可增强抗血脂作用。
• Novel remedies with the use of beta 3 agonist
  申请人：——

  公开号：US20030018061A1

  公开（公告）日：2003-01-23

  Provided is a therapeutic agent comprising at least one member selected from the group consisting of an anticholinergic agent, a monoamine reuptake inhibitor, a lipase inhibitor, a selective serotonin reuptake inhibitor, insulin, an insulin secretagogue, biguanide, an &agr;-glucosidase inhibitor, an insulin resistance improving agent, a HMG-CoA reductase inhibitor, an anion exchange resin, a clofibrate type drug and a nicotinic acid type drug, and a compound having a &bgr;3 agonist activity. The &bgr;3-agonist has an activity of inhibiting dysuria. Further, when used together with a remedy for dysuria such as propiverine, oxybutynin hydrochloride or tolterodine, it exerts an enhanced anti-dysuria effect. When used together with an antiobestic agent such as sibutramine or orlistat, it exerts an enhanced antiobestic effect. When used together with an antidiabetic agent such as insulin, glibenclamide, acarbose or rosiglitazone, it exerts an enhanced antidiabetic effect. When used together with an antilipemic agent such as bezafibrate or pravastatin, it exerts an enhanced antilipemic effect.

  本发明提供了一种治疗剂，它包含至少一种选自以下组别的成员：抗胆碱能药、单胺再摄取抑制剂、脂肪酶抑制剂、选择性5-羟色胺再摄取抑制剂、胰岛素、胰岛素促泌剂、双胍类、&agr；-糖苷酶抑制剂、胰岛素抵抗改善剂、HMG-CoA 还原酶抑制剂、阴离子交换树脂、氯贝特类药物和烟酸类药物，以及具有 &bgr;3 激动剂活性的化合物。&bgr;3-激动剂具有抑制排尿困难的活性。此外，当与治疗排尿困难的药物如丙哌瑞林、盐酸奥昔布宁或托特罗定一起使用时，它能发挥更强的抗排尿困难作用。与西布曲明或奥利司他等抗呕吐剂一起使用时，可增强抗呕吐效果。与胰岛素、格列本脲、阿卡波糖或罗格列酮等抗糖尿病药同时使用时，可增强抗糖尿病效果。与贝扎贝特或普伐他汀等抗血脂药同时使用时，可增强抗血脂作用。
• Amino-substituted tricyclic derivatives and methods of use
  申请人：Schrimpf R. Michael

  公开号：US20050171079A1

  公开（公告）日：2005-08-04

  Compounds of formula (I) wherein A and B are amine-substituted sidechains, Y 1 and Y 2 form various tricyclic cores, and R x is an optional substituent. Compounds and compositions of formula (I) are contemplated as well as methods for treating conditions or disorders prevented by or ameliorated by α7 nAChR ligands that encompass compounds of formula (I) and other tricyclic derivatives.

  其中A和B是胺基取代的侧链，Y1和Y2形成各种三环核，Rx是可选的取代基。考虑到公式(I)的化合物和组合物，以及用于治疗由α7 nAChR配体预防或改善的疾病或疾病的方法，这些方法涵盖了公式(I)的化合物和其他三环衍生物。